Morning Seminar April 28, 2006

The Japan Pediatric Society
109th Annual Meeting (2006.4 Kanazawa)

Morning Seminar April 27, 2006

Cancer. 2006 Feb 1;106(3):703-7.

Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma.

Bisogno G, Riccardi R, Ruggiero A, Arcamone G, Prete A, Surico G, Provenzi M, Bertolini P, Paolucci P, Carli M.

Morning Seminar April 25, 2006

Cancer. 2005 Apr 15;103(8):1659-69.

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.

Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.

How about the long-term effect of imatinib on pediatric patients?

Morning Seminar April 21, 2006

Transplantation for infants with acute leukemia.
Jean E. Sanders

The role of SCT for infants with either ALL or AML remains controversial.


Blood. 2004 Dec 1;104(12):3527-34. Epub 2004 Aug 5.

Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation.

Kosaka Y, Koh K, Kinukawa N, Wakazono Y, Isoyama K, Oda T, Hayashi Y, Ohta S, Moritake H, Oda M, Nagatoshi Y, Kigasawa H, Ishida Y, Ohara A, Hanada R, Sako M, Sato T, Mizutani S, Horibe K, Ishii E.


J Clin Oncol. 2006 Jan 1;24(1):145-51.

Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.

Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE.


Blood. 2005 May 1;105(9):3749-56.

Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.

Sanders JE, Im HJ, Hoffmeister PA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG, Bryant EM, Appelbaum FR.

Morning Seminar April 19, 2006

J Clin Oncol. 2001 Jul 15;19(14):3397-405.

Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.

Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK.

PET is useful to evaluate lesions for neuroblastoma.
How about other pediatric malignancies such as rhabdomyosarcoma?

Morning Seminar April 18, 2006

Blood. 2004 Oct 15;104(8):2254-62.

Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB, Maloney DG, Heimfeld S, Oparin D, Zellmer E, Radich JP, Grumet FC, Blume KG, Chauncey TR, Little MT.

Paper

Morning Seminar April 14, 2006

Blood. 2006 Mar 1;107(5):1800-5.

Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.

Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA.

Paper

Morning Seminar April 13, 2006

Chemotherapy for choroid plexus carcinoma

1. Chemotherapy of choroid plexus carcinoma
Greenberg, Child's Nerv syst 1999, 15: 571-7

Paper

2. Successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome
Dickens, J Pediat Hematol Oncol 2005, 27(1): 46-9

Paper

3. Is there a requirement for adjuvant therapy for choroid plexus carcinoma that has been completely resected?
Fitzpatrick, J Neurooncol 2002, 57: 123-6

Paper

Morning Seminar April 11, 2006

Osaka RA Forum

Infliximab for RA.

Morning Seminar Vol 5(3) March 2006

Sedation 143

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer (Nat Med 2005) 149

Paper

Radiotherapy for neuroblastoma 153

Comparison of conventional to intensity modulated radiation therapy for abdominal NB (Pediatr Blood Cancer 2005) 155

Paper

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhea (Lancet Oncol 2005) 163

Paper

28th The Japan Society for Hematopoietic Cell Transplantation Anuual Meeting (February 24-25, 2006 Tokyo)
Part I 168
Part II 176
Part III 181

Biology of NB that were found by mass screening at 6 months of age in Japan (Pediatr Blood Cancer 2006) 184

Paper

Stem cell transplant for aplastic anemia 188

Tumour markers are poor predictors for relapse or progression in NB (Eur J Cancer 2003) 193

Paper

Long-term acyclovir for prevention of VZV disease after allogeneic hematopoietic cell transplantation – a randomized double-blind placebo-controlled study (Blood 2006) 197

Paper

Late onset ommaya reservoir infection 201

Few but severe viral infections in children with cancer: a prospective RT-PCR and PCR-based 12-month study (Pediatr Blood Cancer 2005) 203

Paper

Patient service for the hearing impaired 210

4th Candin Study Group (March 18, 2006 Tokyo) 216

Comparison of micafungin and liposomal AMPH-B for invasive candidiasis 226

4th Osaka Pediatric Asthma Study Group (March 25, 2006 Osaka) 230

Morning Seminar Vol 5(2) February 2006

Clinical guide for aplastic anemia 51

Improved response in high-risk NB with protracted topotecan administration using a pharmacokinetically guided dosing approach (JCO 2005) 54

Paper

2nd Cord Blood Group Meeting (January 27, 2006 Tokyo) 58

Pediatric AML: international progress and future directions (Leukemia 2005) 66

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials (Leukemia 2005) 69

Paper

Car safety seats: A guide of AAP 2005 75

Altered food intake and taste perception in children with cancer after start of chemotherapy: perspectives of children, parents and nurses (Support Care in Cancer 2006) 80

Paper

Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients (Clin Microbiol Infect 2006) 89

Paper

Pulse steroids: How much is enough (Autoimmun Rev 2005) 97

Paper

Nocardiosis 101

Allogeneic BMT for children with AML in first remission demonstrates a role for GVL in the maintenance of DFS (Blood 2004) 109

Paper

Phase II study of Nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the COG (JCO 2005) 113

Paper

Revision of medical service fee 2006 117

The impact of early resection of primary NB on the survival of children older than 1 year of age with stage 4 disease (Cancer 2005) 123

Paper

Safety and QOL for donor and recipient of SCT Group Meeting (January 27-28, 2006) 127

Consensus guideline for diagnosis and treatment of childhood ITP (Int J Hematol 2006) 135

Paper

Morning Seminar Vol 5(1) Janurary 2006

Heparin-induced thrombocytopenia: an update (Franchini, Thromb J 2005) 1

Paper

Immunopathogenesis and therapy of cutaneous T cell lymphoma (Kim, JCI 2005) 3

Paper

Nakahata group / Horibe group Meeting 2005 (December 18, 2005) 9

Markers of bacteremia in febrile neutropenic patients (von Lilienfeld-Toal, Eur J Microbiol Infect Dis) 15

Paper

Clinical aspects and treatment of pain in children and adolescents with cancer (Monteiro Caran, Pediatr Blood Cancer 2005) 17

Paper

High-carolie fluid therapy 25

The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group (Shanafelt, Oncology 2005) 35

Paper

Treatment of relapsed Wilms’ Tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children’s Memorial Hospital (Cambell, JCO 2004) 41

Paper

6th Pediatric Leukemia Forum (December 17, 2005 Kyoto) 45

Morning Seminar Vol 4(3) December 2005

21st Jpn Pediatr Cancer, 47th Jpn Pediatr Hematol/Oncol Annual Meeting
#1 185
#2 191
#3 198
#4 202

28th Osaka Pediatric Infection Forum (December 12, 2005 Osaka) 207

Volumetric consideration in radiotherapy for pediatric parameningeal rhabdomyosarcomas (Chen, Int J Rad Oncol 2003) 222

Influenza-associated encephalopathy 227

High dose Melphalan in the treatment of advanced NB: Results of a randomised trial (ENSG-1) by the European NB study group (Pritchard, Pediatr Blood Cancer 2005) 230

1st Education Program (The Japanese Society of Hematology) 235

Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic SCT recipients (Aisa, Support Care Cancer 2005) 242

Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil (Nikoletti, J Clin Nurs 2005) 244

Risk factors for bronchiolitis obliterans in allogeneic hematopoietic SCT for leukemia (Santo Tomas, Chest 2005) 245

ASH2005 (December 10-13, 2005 Atlanta) 249

Morning Seminar Vol 4(2) November 2005

Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable NB: results of SFOP NBL90 study (Bergeron, Pediatr Blood Cancer 2005) 107

Hunter disease 110

Long-term follow-up following BMT for Hunter disease (Vellodi, J Inher Metab Dis 1999) 111

Immunodeficiency in children with ALL after completion of modern aggressive chemotherapeutic regimens (Brodtman, J Pediatr 2005) 114

Nodular fasciitis 120

Influence of different therapeutic strategies on exhaled NO and lung inflammation in asthma and COPD (Kharitonov, Vascul Pharmacol 2005) 125

Corticosteroid resistance in airway disease (Proc Am Thorac Soc 2004) 129

Childhood cancer survivors: How to manage hypopituitarism after finalization of growth (Dr. A Toogood　November 4, 2005) 131

Bilateral optic disc oedema as the initial mafifestation of leukaemic relapse (Minamoto, Br J Haematology 2005) 135

Leukemic optic neuropathy complicating leukemia cutis (Hon, JCO 2005) 136

Papilledema, presenting as reversible loss of vision, in a child with ALL (Iqbal, Pediatr Blood Cancer 2005) 138

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial ALL-relapse study of the BFM group 87 (Einsiedel, JCO 2005) 140

No evidence that FLT3 status should be considered as an indicator for transplantation in AML: an analysis of 1135 patients, excluding APL, from the UK MRC AML 10 and 12 trials (Gale, Blood 2005) 144

Tacrolimus-associated posterior reversible encephalopathy syndrome after aloogeneic haematopoietic SCT (Wong, Br J Haematol 2003) 151

Long-term follow-up status of patients with NB after undergoing either aggressive surgery or chemotherapy – A single institution study (Kubota, J Pediatr surgery 2004) 156

Fatal avian Influenza A (H5N1) in child presenting with diarrhea followed by coma (de Jong, NEJM 2005) 162

Probable person-to-person transmission of avian Influenza A (H5N1) (Ungchusak, NEJM 2005) 164

B-cell depletion in the treatment of patients with SLE: a longitudinal analysis of 24 patients (Leandro, Rheumatology 2005) 168

Bone mineral density and serum bone turnover markers in survivors of childhood ALL: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments. (Alikasifoglu, Am J Hematol 2005) 171

2005 ASCO 177

Morning Seminar Vol 4(1) October 2005

SIOP 2005 (2005.9) #1
RMS, soft tissue sarcoma 1

SIOP 2005 (2005.9) #2
medulloblastoma, ependimoma 6

SIOP 2005 (2005.9) #3
Infant brain tumors 13

SIOP 2005 (2005.9) #4
CNS embryonal tumor, medulloblastoma 16

Treatment of medulloblastoma with post operative chemotherapy alone: an SFOP prospective trial in young children (Grill, Lancet Oncol 2005) 28

Resurgence of pertussis in Europe (Calentano, Pediatr Infect Dis J 2005) 35

Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival (Fuhrer, Blood 2005)　39

SCT for patient with Down syndrome 44

Drotrecogin Alfa (Activated) for adults with severe sepsis and a low risk of death (Abraham, N Engl J Med 2005) 47

Biphosphonates and cancer-induced bone disease: beyond their antiresorptive activity (Clezardin, Cancer Research 2005) 53

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory cGVHD (Canninga-van Dijk, Blood 2004) 56

Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin (Lopez-Guillermo, JCO 2005) 60

Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised double-blind, placebo-controlled study (Weijl, Eur J Cancer 2004) 64

Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma (Mazzoleni, Cancer 2005) 69

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial (Berthold, Lancet Oncol 2005) 76

11th Hematology Seminar （October 15-16, 2005 Tokyo） 81

HLA typing for liver transplant 85

Asthma as a consequence of BMT (Rietz, Chest 2002) 92

Long-term acquisition of allergen-specific IgE and asthma following allogeneic BMT from allergic donors (Hallstrand, Blood 2004) 94

Intracranial germ cell tumors: a single institution experience and review of the literature (Smith, J NeuroOncol 2004) 96

Long-term results of a randomized trial on extended use of high dose L-Asparaginase for standard risk childhood ALL (Pession, JCO 2005) 99

Medulloblastoma in childhood: impact of radiation technique upon the outcome of treatment (Chojnacka, Pediatr Blood Cancer 2004) 102

Morning Seminar Vol 3(3) September 2005

Prediction of MYCN amplification in NB; Using serum DNA and real-time quantitative PCR (Gotoh, JCO 2005) 159

The 7th international childhood ALL workshop report: Palermo, Italy, January 29-30,　2005 (Arico, Leukemia 2005) 161

Pain relief for patients with pediatric cancer 165

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic SCT, and prophylactic donor lymphocyte transfusion in high-risk AML and MDS (Schmid, JCO 2005) 170

Allogeneic BMT in children with MDS or JMML: the Seattle experience (Yusuf, BMT 2004) 176

Central venous catheter infection 179

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults (Oxman, N Engl J Med 2005) 187

Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French society of pediatric oncology study (Oyharcabal-Bourden, JCO 2005) 192

Antibacterial prophylaxis after cancer chemotherapy for solid tumors and lymphomas (Cullen, N Engl J Med 2005) 196

Phase I and pharmacokinetic study of Gefitinib in children with refractory solid tumors: a COG study (Daw, JCO 2005) 202

Group III & IV rhabdomyosarcoma 206

European Intergroup Studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors (Carli, JCO 2004) 207

Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients (Heemskerk, J Infect Dis 2005) 213

Evidence for an age cutoff greater than 365 days for NB risk group stratification in the Children’s Oncology Group (London, JCO 2005) 218

Review of alveolar soft part sarcoma (ASPS) 222

Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence:Third Study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89 (Stevens, JCO 2005) 225

Oncolytic viral therapies (Lin, Cancer Gene Therapy 2004) 233

Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children (Ikarashi, Pedistr Int 2004) 239

Morning Seminar Vol 3(2) August 2005

Outcome for patients with metastatic (M2-3) medulloblastoma treated SIOP/UKCCSG PNET-3 chemotherapy (Taylor, Eur J cancer 2005) 89

Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study (Mertens, JCO 2001) 91

High-risk medulloblastoma 96

Characteristic of candidaemia with Candida albicans compared with non-ablicans Candida species and predictors of mortality (Weinberger, J Hosp Infect 2005) 96

Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children’s hospitals (Zaoutis, Diag Microbiol Infect Dis 2005)
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the US (Ostrosky-Zeichner, Antimicrobial Agents Chemotherapy 2003) 102

L-Asp-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage (Top, Pediatr Blood Cancer 2005) 107

Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation (Tan, Pediatr Blood Cancer 2005) 109

Review of SCTs for NB 113

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 AML (Arceci, Blood 2005) 114


Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical SCT in a patient with relapse of metastatic disease (Koscielniak, JCO 2005) 118

Patients with RMS 121

Infantile hepatic hemangiomas: clinical and imaging findings and their correlation with therapy (Kassarijian, Am J Roentgenol 2004) 122

Primary malignant tumors of the stomach in children (Mahour, J Pediatr Surgery 1980)
Gastric NHL: analysis of 252 patients from a multicenter study (Salvagno, Tumori 1999) 124

How to use abdominal echogram 131

Comparison among L-Asp products 136

J Jpn Pediatr Vol.109 (8), 2005
Criteria for diagnosis of mosquito allergy 146
Interssusception 148

Cyclophosphamide for SLE 154

Publication 2005

1. Int J Hematol. 2005 Apr;81(3):264-8.

Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children.

Kanekiyo T, Hara J, Matsuda-Hashii Y, Fujisaki H, Tokimasa S, Sawada A, Kubota K, Shimono K, Imai K, Ozono K.

Paper

2. Stem Cells. 2005 May;23(5):644-55.

Activation of stem-cell specific genes by HOXA9 and HOXA10 homeodomain proteins in CD34+ human cord blood cells.

Ferrell CM, Dorsam ST, Ohta H, Humphries RK, Derynck MK, Haqq C, Largman C, Lawrence HJ.

Paper

3. Ann N Y Acad Sci. 2005 Jun;1044:109-16.

Hox genes: from leukemia to hematopoietic stem cell expansion.

Abramovich C, Pineault N, Ohta H, Humphries RK.

Paper

4. J Immunol. 2005 Oct 1;175(7):4426-32.

Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation.

Maeda M, Carpenito C, Russell RC, Dasanjh J, Veinotte LL, Ohta H, Yamamura T, Tan R, Takei F.

Paper

Publication 2004

1. FEBS Lett. 2004 Apr 23;564(1-2):147-52.

LRRC8 involved in B cell development belongs to a novel family of leucine-rich repeat proteins.

Kubota K, Kim JY, Sawada A, Tokimasa S, Fujisaki H, Matsuda-Hashii Y, Ozono K, Hara J.

Paper

2. Leukemia. 2004 Sep;18(9):1546-8.

A novel partner gene CIP29 containing a SAP domain with MLL identified in infantile myelomonocytic leukemia.

Hashii Y, Kim JY, Sawada A, Tokimasa S, Hiroyuki F, Ohta H, Makiko K, Takihara Y, Ozono K, Hara J.


3. Exp Hematol. 2004 Oct;32(10):955-61.

Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor.

Matsuda-Hashii Y, Takai K, Ohta H, Fujisaki H, Tokimasa S, Osugi Y, Ozono K, Matsumoto K, Nakamura T, Hara J.

Paper

4. Eur J Haematol. 2004 Aug;73(2):75-84.

Defective long-term repopulating ability in hematopoietic stem cells lacking the Polycomb-group gene rae28.
Kim JY, Sawada A, Tokimasa S, Endo H, Ozono K, Hara J, Takihara Y.

Paper

5. Mol Cell Biol. 2004 Mar;24(5):1907-17.

Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Pineault N, Abramovich C, Ohta H, Humphries RK.

Paper

Publication 2003

1. J Clin Invest. 2003 Dec;112(11):1707-13.

A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans.

Sawada A, Takihara Y, Kim JY, Matsuda-Hashii Y, Tokimasa S, Fujisaki H, Kubota K, Endo H, Onodera T, Ohta H, Ozono K, Hara J.

Paper

2. Clin Infect Dis. 2003 Jan 1;36(1):120-3.

Human herpesvirus 6B infection of the large intestine of patients with diarrhea.

Amo K, Tanaka-Taya K, Inagi R, Miyagawa H, Miyoshi H, Okusu I, Sashihara J, Hara J, Nakayama M, Yamanishi K, Okada S.

Paper

Publication 2002

1. Int J Hematol. 2002 Jan;75(1):72-7.

Establishment of a monosomy 7 leukemia cell line, MONO-7, with a ras gene mutation.

Fujisaki H, Takai K, Akihisa S, Tokimasa S, Matsuda Y, Ohta H, Osugi Y, Kim JY, Hosoi G, Sako M, Hara J.

Paper

2. J Exp Med. 2002 Mar 18;195(6):759-70.

Polycomb group gene rae28 is required for sustaining activity of hematopoietic stem cells.

Ohta H, Sawada A, Kim JY, Tokimasa S, Nishiguchi S, Humphries RK, Hara J, Takihara Y.

Paper

3. Bone Marrow Transplant. 2002 Apr;29(7):595-8.

Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation.

Tokimasa S, Hara J, Osugi Y, Ohta H, Matsuda Y, Fujisaki H, Sawada A, Kim JY, Sashihara J, Amou K, Miyagawa H, Tanaka-Taya K, Yamanishi K, Okada S.

Paper

4. Blood. 2002 Sep 15;100(6):2005-11.

High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients.

Sashihara J, Tanaka-Taya K, Tanaka S, Amo K, Miyagawa H, Hosoi G, Taniguchi T, Fukui T, Kasuga N, Aono T, Sako M, Hara J, Yamanishi K, Okada S.

Paper

5. Blood. 2002 Oct 15;100(8):2858-66.

Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes.

Osugi Y, Vuckovic S, Hart DN.

Paper

Publication 2001

1. Exp Hematol. 2001 Jan;29(1):93-103.

Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage.

Tokimasa S, Ohta H, Sawada A, Matsuda Y, Kim JY, Nishiguchi S, Hara J, Takihara Y.

Paper

2. Bone Marrow Transplant. 2001 May;27(9):977-82.

Serum levels of soluble adhesion molecules in stem cell transplantation-related complications.

Matsuda Y, Hara J, Osugi Y, Tokimasa S, Fujisaki H, Takai K, Ohta H, Kawa-Ha K, Okada S.

Paper

3. Bone Marrow Transplant. 2001 May;27(10):1065-70.

Inverse relationship between human herpesvirus-6 and -7 detection after allogeneic and autologous stem cell transplantation.

Miyoshi H, Tanaka-Taya K, Hara J, Fujisaki H, Matsuda Y, Ohta H, Osugi Y, Okada S, Yamanishi K.

Paper

4. Bone Marrow Transplant. 2001 Jun;27(11):1141-5.

Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.

Ohta H, Matsuda Y, Tokimasa S, Sawada A, Kim JY, Sashihara J, Amo K, Miyagawa H, Tanaka-Taya K, Yamamoto S, Tano Y, Aono T, Yamanishi K, Okada S, Hara J.

Paper

5. Int J Hematol. 2001 Oct;74(3):338-41.

Second transplantation with CD34+ blood cells from an HLA-mismatched related donor after engraftment failure of transplanted cord blood cells.

Ohta H, Kim JY, Sawada A, Tokimasa S, Fujisaki H, Matsuda Y, Osugi Y, Hara J.

Paper

6. Int J Ped Hematol/Oncol. 2001 7(2): 109-16

Intra-arterial high-dose chemothrapy consisting of melphalan and thio-TEPA with stem cell rescue for advanced maxillary tumors.

Osugi Y, Tokimasa S, Fujisaki H, Takai K, Nakanishi K, Matsuda Y, Ohta H, Okada S, Hara J.


7. Int J Pediatr Hematol/Oncol 2001, 7(5-6): 385-90

Multimodal therapy for primary intracranial nongerminomatous malignant germ cell tumor in children and young adults.

Ohta H, Matsuda Y, Osugi Y, Fujisaki H, Tokimasa S, Maruno M, Yoshimine T, Inoue T, Inoue T, Hara J


8. Jpn J Pediatr Hematol 2001, 15(5): 388-95

Retransplantation following graft failure of stem cell transplantation: a single-center experience.

Ohta H, Kim J, Sawada A, Tokimasa S, Fujisaki H, Matsuda Y, Osugi Y, Hara J

Publication 2000

1. DNA Seq. 2000;11(1-2):61-73.

Structure and chromosomal localization of the RAE28/HPH1 gene, a human homologue of the polyhomeotic gene.

Ohta H, Tokimasa S, Zou Z, Funaki S, Kurahashi H, Takahashi Y, Kimura M, Matsuoka R, Horie M, Hara J, Shimada K, Takihara Y.

Paper

2. Int J Hematol. 2000 Jul;72(1):69-73.

Expression of adhesion molecules in childhood B-lineage-cell neoplasms.

Hara J, Matsuda Y, Fujisaki H, Tokimasa S, Ohta H, Osagi Y, Takai K.

Paper

3. Bone Marrow Transplant. 2000 Sep;26(6):681-3.

Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha.

Ohta H, Kawai M, Sawada A, Tokimasa S, Fujisaki H, Matsuda Y, Osugi Y, Okada S, Hara J.

Paper

4. Exp Cell Res. 2000 Oct 10;260(1):96-104.

14-3-3 protein family members have a regulatory role in retinoic acid-mediated induction of cytokeratins in F9 cells.

Takihara Y, Matsuda Y, Irie K, Matsumoto K, Hara J.

Paper

5. Int J Hematol. 2000 Aug;72(2):165-72.

Polycomb-group genes and hematopoiesis.

Takihara Y, Hara J.

Paper

6. Carcinogenesis. 2000 Nov;21(11):2073-7.

Role of the beta isoform of 14-3-3 proteins in cellular proliferation and oncogenic transformation.

Takihara Y, Matsuda Y, Hara J.

Paper

7. Int J Hematol. 2000 Apr;71(3):278-82.

Chronic graft-versus-host disease in children and adolescents after bone marrow transplantation from HLA-matched donors.

Yumura-Yagi K, Inoue M, Sakata N, Okamura T, Yasui M, Nakano T, Nomura K, Nakano T, Park DY, Endo C, Nishiuchi R, Sawada A, Matsuda Y, Oota H, Yoshimoto T, Kawa-Ha K.

Paper

Publication 1999

1. Exp Hematol. 1999 May;27(5):826-33.

Lineage switch in childhood leukemia with monosomy 7 and reverse of lineage switch in severe combined immunodeficient mice.

Fujisaki H, Hara J, Takai K, Nakanishi K, Matsuda Y, Ohta H, Osugi Y, Tokimasa S, Taniike M, Hosoi G, Sako M, Okada S.

Paper

2. Bone Marrow Transplant. 1999 Oct;24(8):919-23.

Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children.

Matsuda Y, Hara J, Miyoshi H, Osugi Y, Fujisaki H, Takai K, Ohta H, Tanaka-Taya K, Yamanishi K, Okada S.

Paper

Publication 1998

1. Bone Marrow Transplant. 1998 Feb;21(4):355-60.

Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors.

Matsuda Y, Hara J, Osugi Y, Fujisaki H, Takai K, Ohta H, Nakanishi K, Tokimasa S, Miyoshi H, Tanaka-Taya K, Yamanishi K, Okada S.

Paper

2. Bone Marrow Transplant. 1998 Jul;22(1):7-12.

Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.

Hara J, Osugi Y, Ohta H, Matsuda Y, Nakanishi K, Takai K, Fujisaki H, Tokimasa S, Fukuzawa M, Okada A, Okada S.

Paper

Morning Seminar Vol 3(1) July 2005

Prognostic factors for relapsed childhood ALL: impact of allogeneic SCT – a report from the Kyushu-Yamaguchi Children’s Cancer Study Group (Matsuzaki, Pediatr Blood Cancer 2005) 1

JACLS Seminar (2005) 5

Kaposiform hemangioendotherioma without Kasabach-Merritt phenomenon (Gruman, J Am Acad Dermatol 2005) 20

2nd JPLSG (2005.6) 24

Management of recurrent NB 27

Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001 (Steinbach, Clin Invest Disease 2003) 39

8th International childhood ALL workshop Ponte di Legno 42

Enteral metronidazole for the prevention of GVHD in pediatric marrow transplant recipients: results of a pilot study (Guthery, BMT 2004) 47

B. cereus infection 48

Voriconazole compared with liposomal Amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever (Walsh, N Engl J Med 2002)
Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis (Herbrecht, N Engl J Med 2002) 50

4th Japanese Pediatric Brain Tumor Consortium (2005.6.25) 54

SVC syndrome of malignant origin (Porte, Eur J Cardiothorac Surg 2000) 59

45th Pediatric Cancer Conference (2005.6.11) 64

Methotrexate in SLE (Wong, Lupus 2005) 67

Reduced intensity haemopoietic SCT for treatment of non-malignant disease in children (Jacobsohn, Lancet 2004) 70

Aspergillus niger infection in patients with haematological disease: a report of eight cases (Fianchi, Mycoses 2004) 74

An infant with systemic hypertension, renal artery stenosis, and NB (Shinohara, J Pediatr Surg 2004) 76

Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive ALL (Ph ALL) (Wassmann, Blood 2005) 80

Paclitaxel for ovarian cancer　83

Morning Seminar Vol 2 April 2005-June 2005

Basic knowledge of chemotherapy 1

MLD 21

Mutation in TERT, the gene for telomerase RT, in AA (Yamaguchi, N Engl J Med 2005) 22

8th Infant Leukemia Seminar (1) 23

Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment (Jordan, Eur J Cancer 2005) 26

Juvenile granulosa cell tumor 29

HDC with autologous stem cell rescue for children with highrisk and recurrent medulloblastoma and supratentorial PNET (Perez-Martinez, J Neurooncol 2005) 33

8th Infant Leukemia Seminar (2) 36

Antileukemic and long-term effects of two regimens with or without TBI in allogeneic BMT for childhood ALL (Dai, BMT 2004) 38

Taxane chemotherapeutic drugs 41

Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic RMS: A COG study (Demirer, JCO 2004) 46

Arrythmia 48

Cardiac function 52

Serial evaluation of academic and behavioral outcome after treatment cranial radiation in childhood (Mabott, JCO 2005) 54

Hypercalcemia and malignancy 56

Dose intensity and the toxicity and efficacy of allogeneic hematopoietic transplantation (Appelbaum, Leukemia 2005) 63

Thrombotic microangiophathy with diarrhea 67

GVT effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning (Baron, JCO 2005) 75

Congenital pure red cell aplasia 83

Use of Oseltamivir to control influenza complications after BMT (Machado, BMT 2004) 85

Vascular endothelial function in survivors of childhood cancer 90

Kawasaki Disease 98

Final adult height of patients who received hematopoietic cell transplantation in childhood (Sanders, Blood 2005) 100

Analysis of 96 patients with advanced ovarian carcinoma treated with HDC and ASCT (Donato, BMT 2004)
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer (Donato, Gynecol Oncol 2001)

A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia (Cooper, Clin Cancer Res 2004) 104

Symposium for Fludara’s 5th anniversary
Non-myeloablative SCT 108

DNA topoisomerase II in therapy-related APL (N Engl J Med 2005) 110

The Japan Pediatric Society
108th Annual Meeting (2005.4) Part 1 115

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk NB (Kushner, JCO 2004) 118

The effect of first-line imatinib interim therapy on the outcome of allogeneic SCT in adults with newly diagnosed Philadelphia chromosome-positive ALL (Lee, Blood 2005) 120

The Japan Pediatric Society
108th Annual Meeting (2005.4) Part 2 122

Accidental busulfan overdose during conditioning for SCT (Junke, BMT 2005) 125

J Jpn Pediatr 19(2), 2005 129

Somnolence syndrome 136

Allogeneic hematopoietic cell transplantation for infants with ALL (Sanders, Blood 2005) 137

JACLS（MLL-98） 141

RIST #1 143

Genetic subtypes of FHL: correlations with clinical features and CTL/NK cell functions (Blood 2005) 152

RIST #2 155

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone (Rutkowski, N Engl J Med 2005) 159

Rituximab plus short-duration chemotherapy as first-line treatment for follicular NHL: a phase II trial of the Minnie Pearl Cancer Research Network (Hainswroth, JCO 2005) 163

HDF 167

Expression of IL-10 splicing variants is a positive prognostic feature in relapsed ALL (Wu, JCO 2005) 170

Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management (Tabori, Cancer 2005) 173

Postoperative chemotherapy in advanced ovarian granulosa cell tumors (Al-Badawi, Int J Gynecol Cancer 2002) 176

Difference in time to positivity is useful for the diagnosis of catheter-related bloodstream infection in hematopoietic SCT recipients (Abdelkefi, BMT 2005) 178

Unrelated donor SCT compared with chemotherapy for children with ALL in a second remission: a matched-pair analysis (Borgmann, Blood 2003) 182

Tacrolimus-related encephalopathy following allogeneic SCT in children (Kanekiyo, Int J Hematol 2005) 186

Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT (Wong, Br J Haematol 2003) 188

Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose (Minneci, Ann Intern Med 2004) 192

Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with ALL (Stephan, JCO 2005) 196

A prospective randomized study of clinical and economic consequences of using G-CSF following autologous PBPC transplantation in children (Gonzalez-Vincent, BMT 2004) 200

The risk of developing second cancers among survivors of childhood soft tissue sarcoma (Cohen, Cancer 2005) 206

Transplantation of 2 partially HLA-matched umbilical cord blood units with malignant disease (The 6th Nagoya International Blood and Marrow Transplantation Symposium: 21-22 May, 2005) 208

Umbilical CBT in Europe: An Eurocord survey (The 6th Nagoya International Blood and Marrow Transplantation Symposium: 21-22 May, 2005) 216

Sensitivity to L-Asp is not associated with expression levels of AS in t(12;21)+ pediatric ALL (Wendy, Blood 2003) 222

AS expression is linked with L-Asp resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric ALL (Wendy, Blood 2005) 224

Duration of immunosuppressive treatment for cGVHD (Stewart, Blood 2004) 226

CBTs from unrelated donors in patients with Hurler’s syndrome (Staba, N Engl J Med 2004) 230

Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease (Escolar, N Engl J Med 2005) 232

Effect of SCT on seven cases of leucodystrophy 237

J Jpn Pediatr 109 (5), 2005 242

High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international NB staging system stage II and III NB with MYCN amplification (Laprie, Cancer 2004) 245

10th Pediatric MDS Study group （2005.6.5 Tokyo） 249

Ovarian granulosa cell tumors in childhood (Marras-Salmio, Pediatr Hematol Oncol 2002) 257

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from BMT survivor study (Bhatia, Blood 2005) 261

Results of treatment for NB 265

Reports on allogeneic SCT for pediatric solid tumor 267

Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated NB treated in an upfront Phase II investigation window: a Pediatric Oncology Group study (JCO 2004) 268

12th Pediatric AA Study group (2005.6.4 Tokyo) 272

HLA typing of JMDP 277

Aplastic anemia (Brodsky, Lancet 2005) 278

Life-threatening neurological complications after BMT in children (Uckan, BMT 2005) 284

PFAPA (9th Osaka Pediatric Immunology Study Group 2005.6.9) 286

Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial (Benoehr, J Am Soc Nephrol 2005) 294

Use of rituximab to treat refractory Diamond-Blackfan anemia (Morimoto, Eur J Hematol 2005) 297

Steroids prevent engraftment syndrome after autologous hematopoietic SCT without increasing the risk of infection (Mossad, BMT 2005) 300

Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome (Gonzalez-Vincent, BMT 2004) 301

Autologous PBSCT with induction of autologous GVHD in AML (Park, BMT 2003) 303

CIAS1 mutation (CINCA, FCAS, Muckle-Wells syndrome)
304

Asthma as a consequence of BMT (Rietz, Chest 2002) 310

Immune reconstitution after childhood ALL is most severely affected in the high risk group (Torben, Pediatr Blood Cancer 2005) 312

Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic RMS: a children’s oncology group study (Walterhouse, JCO 2004) 316

Micafungin versus fluconazole for prophylaxis against fungal infections during neutropenia in patients undergoing hematopoietic SCT (van Burik, Clin Infect Disease 2004) 320

After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B (Shetelig, Transfusion 2005) 322

Exacerbating factor of allergy after pediatric liver transplantation
325

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone (Rutkowski, N Engl J Med 2005) 332

Neuropsychological performance and QOL of 10 year survivors of childhood medulloblastoma (Maddrey, J Neurooncol 2005) 335

The risk of developing second cancers among survivors of childhood soft tissue sarcoma (Cohen, Cancer 2005) 337

Long term follow-up after splenectomy peformed for ITP (Schwartz, Am J Hematol 2003) 340

Alveolar soft part sarcoma 343